On August 22nd, 2013 the Canadian Agency for Drugs and Technologies in
Health (CADTH) released a call for patient input into Janssen Inc.’s new
HCV drug, SIMEPREVIR. In order to prepare our Patient Group submission
by the Sept. 13th deadline, HepCBC is ASKING for INPUT from HCV+ people
and caregivers from throughout Canada, by Wednesday, Sept. 11th. CLICK HERE
to ADD YOUR VOICE in determining whether this new treatment should be
available in Canada, by contributing your ideas and experiences to
HepCBC’s group submission.